A Stratified Sickle Event Randomized Trial (ASSERT)
Status:
Terminated
Trial end date:
2007-06-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to compare the effects of ICA-17043 to placebo with or without
hydroxyurea (an oral drug used for treatment of sickle cell disease) in patients with sickle
cell disease who have had 2 or more acute sickle-related painful crises requiring a visit to
a medical facility within the past 12 months.
Phase:
Phase 3
Details
Lead Sponsor:
Icagen
Collaborator:
McNeil Consumer & Specialty Pharmaceuticals, a Division of McNeil-PPC, Inc.